NO2017007I1 - Eluxadoline - Google Patents

Eluxadoline

Info

Publication number
NO2017007I1
NO2017007I1 NO2017007C NO2017007C NO2017007I1 NO 2017007 I1 NO2017007 I1 NO 2017007I1 NO 2017007 C NO2017007 C NO 2017007C NO 2017007 C NO2017007 C NO 2017007C NO 2017007 I1 NO2017007 I1 NO 2017007I1
Authority
NO
Norway
Prior art keywords
eluxadoline
Prior art date
Application number
NO2017007C
Other languages
English (en)
Other versions
NO2017007I2 (no
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2017007(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO2017007I1 publication Critical patent/NO2017007I1/no
Publication of NO2017007I2 publication Critical patent/NO2017007I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
NO2017007C 2004-03-15 2017-02-23 Eluxadoline eller en farmasøytisk akseptabel enantiomer, diastereomer, rasemat eller salt derav NO2017007I2 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55334204P 2004-03-15 2004-03-15
PCT/US2005/008339 WO2005090315A1 (en) 2004-03-15 2005-03-14 Novel compounds as opioid receptor modulators

Publications (2)

Publication Number Publication Date
NO2017007I1 true NO2017007I1 (no) 2017-02-23
NO2017007I2 NO2017007I2 (no) 2017-02-23

Family

ID=34962827

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20064660A NO338203B1 (no) 2004-03-15 2006-10-13 Nye forbindelser som opioidreseptor-modulatorer samt anvendelse derav
NO20160916A NO20160916A1 (no) 2004-03-15 2016-05-30 Nye forbindelser som opioidreseptor-modulatorer
NO2017007C NO2017007I2 (no) 2004-03-15 2017-02-23 Eluxadoline eller en farmasøytisk akseptabel enantiomer, diastereomer, rasemat eller salt derav

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20064660A NO338203B1 (no) 2004-03-15 2006-10-13 Nye forbindelser som opioidreseptor-modulatorer samt anvendelse derav
NO20160916A NO20160916A1 (no) 2004-03-15 2016-05-30 Nye forbindelser som opioidreseptor-modulatorer

Country Status (36)

Country Link
US (8) US7741356B2 (no)
EP (5) EP3112352B1 (no)
JP (1) JP4778954B2 (no)
KR (1) KR101166342B1 (no)
CN (2) CN102786476B (no)
AR (2) AR048269A1 (no)
AT (1) ATE516274T1 (no)
AU (1) AU2005224091B2 (no)
BR (1) BRPI0508820B8 (no)
CA (1) CA2560047C (no)
CR (1) CR8655A (no)
CY (3) CY1111927T1 (no)
DK (5) DK2653465T3 (no)
EC (1) ECSP066856A (no)
ES (5) ES2367576T3 (no)
HK (4) HK1099016A1 (no)
HR (4) HRP20110694T1 (no)
HU (2) HUE029852T2 (no)
IL (3) IL178040A (no)
LT (2) LT2653465T (no)
LU (1) LUC00007I2 (no)
ME (3) ME02540B (no)
MX (1) MXPA06010642A (no)
MY (1) MY146972A (no)
NL (1) NL300865I2 (no)
NO (3) NO338203B1 (no)
NZ (1) NZ549842A (no)
PH (1) PH12012501640A1 (no)
PL (4) PL2573068T3 (no)
PT (4) PT2573068E (no)
RS (4) RS52933B (no)
SI (4) SI1725537T1 (no)
TW (1) TWI361069B (no)
UA (1) UA86053C2 (no)
WO (1) WO2005090315A1 (no)
ZA (1) ZA200608587B (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
SI1725537T1 (sl) 2004-03-15 2011-11-30 Janssen Pharmaceutica Nv Nove spojine kot modulatorji opioidnih receptorjev
EA013261B1 (ru) 2004-05-14 2010-04-30 Янссен Фармацевтика, Н.В. Опиоидные соединения, замещенные карбоксамидогруппой
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
MX2007011409A (es) * 2005-03-14 2008-02-22 Johnson & Johnson Procedimiento de preparacion de moduladores opioides.
NZ568595A (en) 2005-12-14 2010-04-30 Bristol Myers Squibb Co Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
WO2007078990A2 (en) 2005-12-23 2007-07-12 Zealand Pharma A/S Modified lysine-mimetic compounds
EP2004697A2 (en) 2006-04-07 2008-12-24 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008079266A2 (en) 2006-12-21 2008-07-03 Wyeth Synthesis of pyrrolidine compounds
WO2009009480A2 (en) * 2007-07-09 2009-01-15 Janssen Pharmaceutica N.V. Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh) * 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
DK2451279T3 (da) 2009-07-06 2019-05-20 Aerpio Therapeutics Inc Benzosulfonamid derivater forbindelser deraf og deres brug til at forhindre metastaser af cancerceller
EP2709985B1 (en) 2011-05-16 2017-10-04 Bionomics Limited Amine derivatives as potassium channel blockers
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
SG11201506972PA (en) 2013-03-14 2015-10-29 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
US9675587B2 (en) * 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
EP2970133B1 (en) * 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
EP3319444B1 (en) 2015-07-09 2022-03-09 The Regents of the University of California Mu opioid receptor modulators
US10314819B2 (en) 2015-07-23 2019-06-11 Teva Pharmaceuticals International Gmbh Solid state forms of Eluxadoline
JPWO2017043626A1 (ja) * 2015-09-11 2018-06-21 株式会社カネカ 光学活性４−カルバモイル−２，６−ジメチルフェニルアラニン誘導体の製造法
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
CN107129444B (zh) * 2016-02-29 2018-08-31 尚科生物医药（上海）有限公司 (s)-2-叔丁氧羰基氨基-3-(4-氨甲酰基-2,6-二甲基苯基)丙酸制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
US20190177281A1 (en) * 2016-05-03 2019-06-13 Sromovasam THIRUMALAI RAJAN Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof
EP3463333A4 (en) * 2016-05-30 2019-11-20 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF ELUXADOLINE
US10822308B2 (en) * 2016-06-23 2020-11-03 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
EP3515434A4 (en) 2016-09-20 2020-02-26 Sun Pharmaceutical Industries Limited METHOD FOR PRODUCING ELUXADOLIN
US10738013B2 (en) 2017-01-27 2020-08-11 Quimica Sintetica, S.A. Eluxadoline crystalline forms and processes for their preparation
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) * 2018-01-25 2019-08-01 四川科伦博泰生物医药股份有限公司 取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en) 2018-04-09 2019-10-17 Quimica Sintetica, S. A. Process for the preparation of opioid modulators
WO2020039333A1 (en) 2018-08-20 2020-02-27 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
ES2867895T3 (es) * 2018-11-30 2021-10-21 Phytobiotics Futterzusatzstoffe Gmbh Sistema para el análisis de imágenes de excrementos de animales
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal
US20230118152A1 (en) 2020-03-30 2023-04-20 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
CA3187393A1 (en) * 2020-07-28 2022-02-03 Andrew BELFIELD Chiral synthesis of fused bicyclic raf inhibitors
US11850319B2 (en) 2020-09-29 2023-12-26 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
US11896728B2 (en) 2020-09-29 2024-02-13 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
EP0805816B1 (en) * 1995-01-27 2004-07-28 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
EP0830347B1 (en) 1995-04-13 2004-09-22 Aventis Pharmaceuticals, Inc. Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
AU6772996A (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
WO1997019908A1 (en) 1995-11-29 1997-06-05 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
US5792760A (en) 1997-04-23 1998-08-11 Eli Lilly And Company Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
PT1055665E (pt) * 1999-05-28 2004-03-31 Pfizer Prod Inc Derivados da 3-(3-hidroxifenil)-3-amino-propionamida
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
US20020072017A1 (en) * 2000-10-19 2002-06-13 Hudnall Phillip Montgomery Stabilized p-phenylenediamine-type photographic color developers in free base form
CN101307046B (zh) 2000-10-30 2012-08-15 詹森药业有限公司 三肽酶抑制剂
KR100898562B1 (ko) * 2001-10-15 2009-05-20 얀센 파마슈티카 엔.브이. 신규 치환된 4-페닐-4-[1ｈ-이미다졸-2-일]-피페리딘유도체 및 선택적인 비펩타이드 델타 아편유사작용제로서의 그의 용도
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
SI1725537T1 (sl) 2004-03-15 2011-11-30 Janssen Pharmaceutica Nv Nove spojine kot modulatorji opioidnih receptorjev
WO2005111028A1 (en) * 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
MX2007011409A (es) * 2005-03-14 2008-02-22 Johnson & Johnson Procedimiento de preparacion de moduladores opioides.

Also Published As

Publication number Publication date
PT2573068E (pt) 2015-04-27
BRPI0508820A (pt) 2007-08-07
CN102786476A (zh) 2012-11-21
US20100324051A1 (en) 2010-12-23
EP2573068A1 (en) 2013-03-27
US10213415B2 (en) 2019-02-26
LT2653465T (lt) 2016-09-12
HRP20110694T1 (hr) 2011-12-31
NZ549842A (en) 2010-10-29
CY1111927T1 (el) 2015-11-04
HK1155726A1 (en) 2012-05-25
EP2298744A2 (en) 2011-03-23
UA86053C2 (ru) 2009-03-25
EP1725537A1 (en) 2006-11-29
BRPI0508820B1 (pt) 2018-04-10
US8772325B2 (en) 2014-07-08
CR8655A (es) 2008-09-09
BRPI0508820B8 (pt) 2022-11-29
KR20060131983A (ko) 2006-12-20
CA2560047A1 (en) 2005-09-29
US8344011B2 (en) 2013-01-01
PH12012501640B1 (en) 2015-10-05
ZA200608587B (en) 2008-06-25
PH12012501640A1 (en) 2015-10-05
LUC00007I1 (no) 2017-03-03
MY146972A (en) 2012-10-15
HRP20150305T1 (hr) 2015-04-24
CA2560047C (en) 2013-12-24
EP2653465B1 (en) 2016-07-13
LTC1725537I2 (lt) 2018-02-26
PT2298744E (pt) 2013-09-12
US20160030393A1 (en) 2016-02-04
CY1118096T1 (el) 2017-06-28
US20180325870A1 (en) 2018-11-15
EP1725537B1 (en) 2011-07-13
NO338203B1 (no) 2016-08-08
HK1099016A1 (en) 2007-08-03
NL300865I2 (nl) 2020-08-17
PL1725537T3 (pl) 2011-12-30
NL300865I1 (nl) 2017-03-14
HUE029852T2 (en) 2017-04-28
EP2573068B9 (en) 2015-08-26
US9205076B2 (en) 2015-12-08
PL2573068T3 (pl) 2015-06-30
EP2653465A1 (en) 2013-10-23
HRP20161331T1 (hr) 2016-12-30
ECSP066856A (es) 2006-11-24
US20140039024A1 (en) 2014-02-06
EP2298744B1 (en) 2013-06-26
AR095848A2 (es) 2015-11-18
US20140256779A1 (en) 2014-09-11
AU2005224091A1 (en) 2005-09-29
US20130090478A1 (en) 2013-04-11
PT2653465T (pt) 2016-09-22
US7786158B2 (en) 2010-08-31
HUS1700010I1 (hu) 2017-03-28
NO20064660L (no) 2006-12-14
US7741356B2 (en) 2010-06-22
DK2573068T3 (en) 2015-02-16
IL178040A0 (en) 2006-12-31
CN1950342A (zh) 2007-04-18
CY2017008I2 (el) 2017-11-14
ATE516274T1 (de) 2011-07-15
NO2017007I2 (no) 2017-02-23
DK3112352T3 (en) 2019-01-28
JP4778954B2 (ja) 2011-09-21
NO20160916A1 (no) 2006-12-14
IL178040A (en) 2013-12-31
KR101166342B1 (ko) 2012-07-18
TW200539876A (en) 2005-12-16
HRP20130800T1 (en) 2013-09-30
ME02221B (me) 2016-02-20
SI2298744T1 (sl) 2013-10-30
EP2298744A3 (en) 2011-08-10
HK1105967A1 (en) 2008-02-29
CN102786476B (zh) 2017-01-18
ME01601B (me) 2014-09-20
SI2573068T1 (sl) 2015-03-31
RS51995B (en) 2012-04-30
DK2298744T3 (da) 2013-09-02
JP2007529527A (ja) 2007-10-25
RS54199B1 (en) 2015-12-31
CY2017008I1 (el) 2017-11-14
LTPA2017005I1 (lt) 2017-03-27
ME02540B (me) 2017-02-20
EP2573068B1 (en) 2014-12-31
PL2653465T3 (pl) 2017-01-31
ES2533176T3 (es) 2015-04-08
PL2298744T3 (pl) 2013-11-29
WO2005090315A1 (en) 2005-09-29
ES2428008T3 (es) 2013-11-05
ES2705077T3 (es) 2019-03-21
IL229444A0 (en) 2013-12-31
ES2367576T3 (es) 2011-11-04
SI2653465T1 (sl) 2016-10-28
DK2653465T3 (da) 2016-08-22
IL224908A (en) 2015-07-30
EP3112352B1 (en) 2018-11-21
AR048269A1 (es) 2006-04-12
US9700542B2 (en) 2017-07-11
ES2596434T3 (es) 2017-01-09
HK1184432A1 (en) 2014-01-24
PT1725537E (pt) 2011-09-08
SI1725537T1 (sl) 2011-11-30
IL229444A (en) 2017-03-30
AU2005224091B2 (en) 2012-02-02
LUC00007I2 (no) 2017-05-02
CN1950342B (zh) 2012-09-26
MXPA06010642A (es) 2007-03-26
US8609709B2 (en) 2013-12-17
RS55122B1 (sr) 2016-12-30
DK1725537T3 (da) 2011-10-31
EP3112352A1 (en) 2017-01-04
RS52933B (en) 2014-02-28
US20050203143A1 (en) 2005-09-15
TWI361069B (en) 2012-04-01
US20080096888A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
CY2019034I2 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
NO2017007I1 (no) Eluxadoline
DE502005005116D1 (de) Wischblatt
DE502005005035D1 (de) Wischblatt
DE502005005628D1 (de) Wischblatt
ATE392425T1 (de) Thiazolyl-dihydro-indazole
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
DE502005004843D1 (de) Einspritzventil
ATE459633T1 (de) Makrolide
DE502005006395D1 (de) Verschlusskappe
DE502005005991D1 (de) Sensorleuchte
DE502005004842D1 (de) Wischblatt
DE112005000809A5 (de) Wankstabilisierungseinrichtung
DE502005008587D1 (de) Kugelgelenk
DE502005007739D1 (de) Kranballastierungssystem
DE502005007584D1 (de) Raftfahrzeuge
DE502005002602D1 (de) Fahrzeugtemperiersystem
DE502005004695D1 (de) Sicherheitsfangseil
DE502004012213D1 (de) Flachdichtung
DE502005007997D1 (de) Aftfahrzeug
AT500198B8 (de) Ladewagen
DE202004017327U1 (de) Fitnessrad
ATE389633T1 (de) Omega-phenyloctanamide
DE112005000794T5 (de) Urethanspritzpistolenanordnung
DE502005007686D1 (de) Gutverteileinrichtung